SEC Form 4 · accession 0001209191-19-007326

NovoCure Ltd · NVCR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

Feb 1, 2019

Accepted (ET)

Feb 5, 2019 · 4:16 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001645113

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares^F1	Feb 1, 2019	M	37,500	$7.15	A	184,058	D
Ordinary Shares^F2	Feb 1, 2019	S	27,660	$48.861	D	156,398	D
Ordinary Shares^F3	Feb 1, 2019	S	9,840	$49.508	D	146,558	D
Ordinary Shares^F1	Feb 4, 2019	M	21,000	$7.15	A	167,558	D
Ordinary Shares^F4	Feb 4, 2019	S	21,000	$49.533	D	146,558	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options to Buy Ordinary Shares^F5	$7.15	Feb 1, 2019	M	37,500	D	—	Feb 21, 2027	Ordinary Shares	37,500	182,513	D
Options to Buy Ordinary Shares^F5	$7.15	Feb 4, 2019	M	21,000	D	—	Feb 21, 2027	Ordinary Shares	21,000	161,513	D

F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi.
F2On February 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 27,660 shares in multiple trades at prices ranging from $48.33 to $49.32. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3On February 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 9,840 shares in multiple trades at prices ranging from $49.33 to $49.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F4On February 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 21,000 shares in multiple trades at prices ranging from $49.08 to $49.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F5Fully vested as of the date hereof.